Welcome to LookChem.com Sign In|Join Free
  • or
BenzaMide, N-[2-(aMinocarbonyl)phenyl]-3-Methoxy-, also known as 3-methoxy-N-(phenylcarbamoyl)benzamide, is a chemical compound belonging to the class of benzamide derivatives. It is a derivative of a potential antitumor agent and is characterized by its unique chemical structure and properties. BenzaMide, N-[2-(aMinocarbonyl)phenyl]-3-Methoxyis often utilized for research purposes and has potential pharmaceutical applications due to its demonstrated biological activities and therapeutic effects, particularly in the treatment of tumors and other diseases.

330657-87-9

Post Buying Request

330657-87-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

330657-87-9 Usage

Uses

Used in Pharmaceutical Research and Development:
BenzaMide, N-[2-(aMinocarbonyl)phenyl]-3-Methoxyis used as a research compound for exploring its potential therapeutic effects. Its unique structure and properties make it a valuable target for the development of new drugs, particularly in the area of oncology.
Used in Oncology:
In the field of oncology, BenzaMide, N-[2-(aMinocarbonyl)phenyl]-3-Methoxyis used as a potential antitumor agent. It has been studied for its ability to target and treat various types of tumors, offering a promising avenue for cancer therapy.
Used in Drug Discovery:
BenzaMide, N-[2-(aMinocarbonyl)phenyl]-3-Methoxyis utilized in drug discovery processes to identify and develop new pharmaceuticals with improved efficacy and safety profiles. Its biological activities and potential therapeutic effects make it a valuable candidate for further investigation and optimization in the development of novel drugs.
Used in Biological Research:
In biological research, BenzaMide, N-[2-(aMinocarbonyl)phenyl]-3-Methoxyserves as a tool compound to study various biological processes and mechanisms. Its unique properties allow researchers to gain insights into the molecular interactions and pathways involved in diseases, which can contribute to the understanding of disease pathogenesis and the identification of new therapeutic targets.

Check Digit Verification of cas no

The CAS Registry Mumber 330657-87-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,0,6,5 and 7 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 330657-87:
(8*3)+(7*3)+(6*0)+(5*6)+(4*5)+(3*7)+(2*8)+(1*7)=139
139 % 10 = 9
So 330657-87-9 is a valid CAS Registry Number.

330657-87-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(2-carbamoylphenyl)-3-methoxybenzamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:330657-87-9 SDS

330657-87-9Relevant academic research and scientific papers

Competing HB acceptors: An extensive NMR investigations corroborated by single crystal XRD and DFT calculations

Tiwari, Surbhi,Arya, Neeru,Mishra, Sandeep Kumar,Suryaprakash

, p. 15195 - 15202 (2021/05/21)

A series of N-benzoylanthranilamide derivatives have been synthesized with the substitution of competitive HB acceptors and investigated by NMR spectroscopy and single crystal XRD. The interesting rivalry for HB acceptance between CO and X (F or OMe) is observed in the investigated molecules which leads to an unusual increase in the electron density at the site of one of the NH protons, reflecting in the high field resonance in the 1H NMR spectrum. The NMR experimental findings and single crystal XRD are further reinforced by the DFT studies.

N-Phenylbenzamide derivatives as alternative oxidase inhibitors: Synthesis, molecular properties, 1H-STD NMR, and QSAR

Barsottini, Mario R. O.,Carazzolle, Marcelo F.,Costa, Paulo C. S.,Evangelista, Joel S.,Miranda, Paulo C. M. L.,Nascimento, Andrey F. Z.,Pereira, Gon?alo A. G.,Pires, Bárbara A.,Rocco, Silvana A.,Sfor?a, Maurício L.,Silva, Jaqueline S.,Vieira, Maria L. L.,Zeri, Ana C. M.

, (2020/02/27)

In the present work, 117 N-phenylbenzamides (NPDs) were prepared and evaluated against recombinant AOX from the fungal pathogen Moniliophthora perniciosa. 1H, 13C NMR, FTIR, and mass spectra provided structural information on NPDs. The library compounds were tested as Alternative Oxidase inhibitors in two different assays using the model yeast Pichia pastoris: cell growth and oxygen consumption assays. The most active compound, 3FH, was further characterized by DRX and 1H-NMR-STD. Single crystal X-ray diffraction showed intra- and intermolecular interactions of 3FH in solid-state and elucidated its 3D structural configuration. 1H-NMR-STD allowed us to derive protein-ligand interactions in a membrane-mimetic system and evidenced an outstanding interaction of 3FH with this enzyme. Results of both biological assays were used as input to Quantitative Structure-Activity Relationship models, which highlighted the more important molecular fragments contributions for protein-ligand interaction.

RHO KINASE INHIBITORS

-

Page/Page column 99; 100, (2010/10/03)

The present invention relates to inhibitors of ROCK1 and ROCK2, which may be selective for ROCK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and/or ROCK2. Also provided are treatments combining inhibitors of ROCK1 and/or ROCK2 with statins.

RHO KINASE INHIBITORS

-

Page/Page column 104, (2008/12/05)

The present invention relates to inhibitors of ROCKl and R0CK2, which may be selective for R0CK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and/or R0CK2. Also provided are treatments combining inhibitors of ROCKl and/or R0CK2 with statins.

PHARMACOKINETICALLY IMPROVED COMPOUNDS

-

Page/Page column 88, (2010/11/24)

The present invention relates to inhibitors of ROCKl and R0CK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that are useful for the treatment of disease.

Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors

Hayakawa, Masahiko,Kaizawa, Hiroyuki,Moritomo, Hiroyuki,Koizumi, Tomonobu,Ohishi, Takahide,Okada, Minoru,Ohta, Mitsuaki,Tsukamoto, Shin-ichi,Parker, Peter,Workman, Paul,Waterfield, Mike

, p. 6847 - 6858 (2007/10/03)

A series of 4-morpholino-2-phenylquinazolines and related derivatives were prepared and evaluated as inhibitors of PI3 kinase p110α. In this series, the thieno[3,2-d]pyrimidine derivative 15e showed the strongest inhibitory activity against p110α, with an

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 330657-87-9